BidaskClub upgraded shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) from a buy rating to a strong-buy rating in a report issued on Saturday.

ALXN has been the topic of several other reports. BMO Capital Markets reissued an outperform rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Zacks Investment Research raised Alexion Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, April 18th. Raymond James Financial, Inc. reissued a strong-buy rating and set a $176.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 9th. Goldman Sachs Group, Inc. (The) reissued a buy rating and set a $142.00 price target on shares of Alexion Pharmaceuticals in a research report on Friday, June 9th. Finally, Leerink Swann reissued a buy rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $156.89.

Shares of Alexion Pharmaceuticals (ALXN) opened at 138.33 on Friday. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $145.41. The firm has a 50-day moving average price of $125.22 and a 200 day moving average price of $122.56. The stock has a market cap of $30.87 billion, a PE ratio of 59.99 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.48. The firm had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.13 earnings per share. Equities research analysts predict that Alexion Pharmaceuticals will post $5.57 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Lifted to “Strong-Buy” at BidaskClub” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/08/alexion-pharmaceuticals-inc-alxn-lifted-to-strong-buy-at-bidaskclub.html.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average price of $116.72 per share, for a total transaction of $1,167,200.00. Following the purchase, the chief executive officer now directly owns 38,725 shares in the company, valued at $4,519,982. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bros. Advisors Lp Baker bought 660,779 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were acquired at an average price of $117.33 per share, with a total value of $77,529,200.07. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 2,019,734 shares of company stock valued at $235,606,846. 4.35% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Guardian Life Insurance Co. of America increased its stake in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the last quarter. Eqis Capital Management Inc. increased its stake in shares of Alexion Pharmaceuticals by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,776 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 38 shares in the last quarter. Grandfield & Dodd LLC increased its stake in shares of Alexion Pharmaceuticals by 1.5% in the first quarter. Grandfield & Dodd LLC now owns 3,270 shares of the biopharmaceutical company’s stock worth $396,000 after buying an additional 47 shares in the last quarter. Cleararc Capital Inc. increased its stake in shares of Alexion Pharmaceuticals by 1.0% in the first quarter. Cleararc Capital Inc. now owns 5,495 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 53 shares in the last quarter. Finally, Seven Bridges Advisors LLC increased its stake in shares of Alexion Pharmaceuticals by 2.1% in the second quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 53 shares in the last quarter. Hedge funds and other institutional investors own 95.14% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.